1. “Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer”
by Lopez-Beltran, A.; Cimadamore, A.; Blanca, A.; Massari, F.; Vau, N.; Scarpelli, M.; Cheng, L. and Montironi, R.
Cancers 2021, 13(1), 131; https://doi.org/10.3390/cancers13010131
Available online: https://www.mdpi.com/2072-6694/13/1/131
2. “IL-12 Family Cytokines in Cancer and Immunotherapy”
by Mirlekar, B. and Pylayeva-Gupta, Y.
Cancers 2021, 13(2), 167; https://doi.org/10.3390/cancers13020167
Available online: https://www.mdpi.com/2072-6694/13/2/167
3. “STING Agonists as Cancer Therapeutics”
by Amouzegar, A.; Chelvanambi, M.; Filderman, J. N.; Storkus, W. J. and Luke, J. J.
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
Available online: https://www.mdpi.com/2072-6694/13/11/2695
4. “Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma”
by Ferrucci, P. F.; Pala, L.; Conforti, F. and Cocorocchio, E.
Cancers 2021, 13(6), 1383; https://doi.org/10.3390/cancers13061383
Available online: https://www.mdpi.com/2072-6694/13/6/1383
5. “Senolytics for Cancer Therapy: Is All that Glitters Really Gold?”
by Carpenter, V. J.; Saleh, T. and Gewirtz, D. A.
Cancers 2021, 13(4), 723; https://doi.org/10.3390/cancers13040723
Available online: https://www.mdpi.com/2072-6694/13/4/723
6. “CTLA-4 in Regulatory T Cells for Cancer Immunotherapy”
by Sobhani, N.; Tardiel-Cyril, D. R.; Davtyan, A.; Generali, D.; Roudi, R. and Li, Y.
Cancers 2021, 13(6), 1440; https://doi.org/10.3390/cancers13061440
Available online: https://www.mdpi.com/2072-6694/13/6/1440
7. “The Role of Macrophages in Cancer Development and Therapy”
by Cendrowicz, E.; Sas, Z.; Bremer, E. and Rygiel, T. P.
Cancers 2021, 13(8), 1946; https://doi.org/10.3390/cancers13081946
Available online: https://www.mdpi.com/2072-6694/13/8/1946
8. “The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment”
by Haist, M.; Stege, H.; Grabbe, S.; Bros, M.
Cancers 2021, 13(2), 210; https://doi.org/10.3390/cancers13020210
Available online: https://www.mdpi.com/2072-6694/13/2/210
9. “Immune Resistance in Lung Adenocarcinoma”
by Spella, M. and Stathopoulos, G. T.
Cancers 2021, 13(3), 384; https://doi.org/10.3390/cancers13030384
Available online: https://www.mdpi.com/2072-6694/13/3/384
10. “Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases”
by Bailly, C.; Thuru, X. and Quesnel, B.
Cancers 2021, 13(12), 3034; https://doi.org/10.3390/cancers13123034
Available online: https://www.mdpi.com/2072-6694/13/12/3034
